{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:55:18Z","timestamp":1740146118532,"version":"3.37.3"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2016,12,28]],"date-time":"2016-12-28T00:00:00Z","timestamp":1482883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0168544","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T16:07:15Z","timestamp":1483978035000},"page":"e0168544","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment"],"prefix":"10.1371","volume":"11","author":[{"given":"Christoph","family":"Sarrazin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Manns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Luis","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Garcia-Samaniego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee","family":"Kaste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry O.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,12,28]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"K Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"unstructured":"EASL. EASL recommendation on treatment of hepatitis C. Available at. 2014;http:\/\/files.easl.eu\/easl-recommendations-on-treatment-of-hepatitis-C.pdf<\/ext-link>.","key":"ref2"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/cid\/cir306","article-title":"All-cause, liver-related, and non-liver-related mortality among HCV-infected individuals in the general US population","volume":"53","author":"SS El-Kamary","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1478-3231.2011.02537.x","article-title":"The global health burden of hepatitis C virus infection","volume":"31","author":"F Negro","year":"2011","journal-title":"Liver Int"},{"issue":"1 Suppl","key":"ref5","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"E Gower","year":"2014","journal-title":"Journal of hepatology"},{"unstructured":"Janssen Products, L. P. OLYSIO\u2122 (simeprevir) Prescribing Information 2014 [accessed November 2014].","key":"ref6"},{"unstructured":"Gilead Sciences I. SOVALDITM (sofosbuvir) prescribing information. 2013.","key":"ref7"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges","volume":"146","author":"JM Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1128\/AAC.00787-10","article-title":"Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease","volume":"54","author":"PW White","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.jhep.2010.08.040","article-title":"Potency, safety, and pharmacokinetics of the NS3\/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection","volume":"54","author":"MP Manns","year":"2011","journal-title":"J Hepatol"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1128\/AAC.00565-13","article-title":"Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C","volume":"57","author":"D Larrey","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1021\/jm4011862","article-title":"Conformation-based restrictions and scaffold replacements in the design of hepatitis C virus polymerase inhibitors: discovery of deleobuvir (BI 207127)","volume":"57","author":"SR LaPlante","year":"2014","journal-title":"J Med Chem"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3851\/IMP2567","article-title":"Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results","volume":"18","author":"S Zeuzem","year":"2013","journal-title":"Antivir Ther"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and Deleobuvir for HCV Genotype 1 Infection","volume":"369","author":"S Zeuzem","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/liv.12693","article-title":"Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study","volume":"35","author":"S Zeuzem","year":"2015","journal-title":"Liver Int"},{"key":"ref16","article-title":"HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-na\u00efve patients with chronic hepatitis C virus genotype-1b infection","author":"C Sarrazin","year":"2016","journal-title":"Clin Exp Gastroenterol"},{"key":"ref17","article-title":"Why is viral eradication so important in patients with HCV-related cirrhosis?","author":"J Velosa","year":"2016","journal-title":"Antivir Ther"},{"key":"ref18","article-title":"Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)","author":"M Bourliere","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"21","key":"ref19","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"F Poordad","year":"2014","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0168544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T07:05:21Z","timestamp":1540019121000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0168544"}},"subtitle":[],"editor":[{"given":"Chien-Wei","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,12,28]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0168544","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2016,12,28]]}}}